Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 16/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043718 | 0.93 | CSNK1E (0.41) | KMT2ACSNK1EMEN1 | |
| SCHEMBL4046474 | 0.90 | CSNK1E (0.41) | CSNK1E | |
| SCHEMBL14394090 | 0.89 | CSNK1E (0.37) | CSNK1E | |
| SCHEMBL4037674 | 0.88 | CSNK1E (0.42) | KMT2ACSNK1EMEN1 | |
| SCHEMBL4041961 | 0.86 | PKM (0.47) | KMT2AKDM4EMEN1 | |
| SCHEMBL4041930 | 0.85 | CSNK1E (0.43) | KMT2ACSNK1EMEN1 | |
| SCHEMBL13964125 | 0.81 | CSNK1E (0.49) | CSNK1E | |
| SCHEMBL13964296 | 0.81 | MEN1 (0.35) | KMT2AFKBP1ACSNK1EMEN1 | |
| SCHEMBL4044206 | 0.80 | KMT2A (0.42) | KMT2ACSNK1EMEN1 | |
| SCHEMBL4038956 | 0.80 | KMT2A (0.42) | KMT2ACSNK1EKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569375-B2 | Alcohol dehydrogenases with increased solvent and temperature stability | CODEXIS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| EP-1483273-B1 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| EP-1485471-B1 | ALCOHOL DEHYDROGENASES WITH HIGH SOLVENT AND TEMPERATURE STABILITY | BIOCATALYTICS INC (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-7094907-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2006-08-22 | — | — | US | disclosed |
| EP-1664286-A1 | ALCOHOL DEHYDROGENASES WITH INCREASED SOLVENT AND TEMPERATURE STABILITY | Ciba SC Holding AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1485471-A1 | ALCOHOL DEHYDROGENASES WITH HIGH SOLVENT AND TEMPERATURE STABILITY | Ciba SC Holding AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| EP-1483273-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | Solvias AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167018-A1 | Palladium catalysts | VAN DER SCHAAF PAUL ADRIAAN (CH) | 2004-08-26 | — | — | US | disclosed |
| US-20040157305-A1 | Alcohol dehydrogenases with increased solvent and temperature stability | CODEXIS, INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| EP-1414566-A1 | PALLADIUM CATALYSTS | Ciba SC Holding AG (CH) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003078615-A1 | ALCOHOL DEHYDROGENASES WITH HIGH SOLVENT AND TEMPERATURE STABILITY | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003031456-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003013723-A1 | PALLADIUM CATALYSTS | CIBA SPECIALITY CHEMICALS HOLDING INC. (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | KMT2A 2686/4885FKBP1A 400/4885GLA 3131/4885 |
| US-20040167018-A1 | Palladium catalysts | PDCD1LG2, CD274, MT-CO3 | KMT2A 2068/4885FKBP1A 3721/4885GLA 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.